Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Two case studies of patients with major depressive disorder given low-dose (subanesthetic) ketamine infusions.

× No keyword cloud information.

19 in total

1. CD-1 and Balb/cJ mice do not show enduring antidepressant-like effects of ketamine in tests of acute antidepressant efficacy.

Authors: Anita J Bechtholt-Gompf; Karen L Smith; Catherine S John; Hannah H Kang; William A Carlezon; Bruce M Cohen; Dost Ongür
Journal: Psychopharmacology (Berl) Date: 2011-01-28 Impact factor: 4.530

Review 2. Ketamine for depression: where do we go from here?

Authors: Marije Aan Het Rot; Carlos A Zarate; Dennis S Charney; Sanjay J Mathew
Journal: Biol Psychiatry Date: 2012-06-16 Impact factor: 13.382

Review 3. Ketamine for treatment-resistant unipolar depression: current evidence.

Authors: Sanjay J Mathew; Asim Shah; Kyle Lapidus; Crystal Clark; Noor Jarun; Britta Ostermeyer; James W Murrough
Journal: CNS Drugs Date: 2012-03-01 Impact factor: 5.749

4. Lack of persistent effects of ketamine in rodent models of depression.

Authors: Piotr Popik; Tomasz Kos; Magdalena Sowa-Kućma; Gabriel Nowak
Journal: Psychopharmacology (Berl) Date: 2008-05-07 Impact factor: 4.530

5. What is hydroxynorketamine and what can it bring to neurotherapeutics?

Authors: Nagendra S Singh; Carlos A Zarate; Ruin Moaddel; Michel Bernier; Irving W Wainer
Journal: Expert Rev Neurother Date: 2014-11 Impact factor: 4.618

6. Daily oral ketamine for the treatment of depression and anxiety in patients receiving hospice care: a 28-day open-label proof-of-concept trial.

Authors: Scott A Irwin; Alana Iglewicz; Richard A Nelesen; Jessica Y Lo; Connie H Carr; Sheilani D Romero; Linda S Lloyd
Journal: J Palliat Med Date: 2013-06-27 Impact factor: 2.947

Two case studies of patients with major depressive disorder given low-dose (subanesthetic) ketamine infusions.

1. CD-1 and Balb/cJ mice do not show enduring antidepressant-like effects of ketamine in tests of acute antidepressant efficacy.

Review 2. Ketamine for depression: where do we go from here?

Review 3. Ketamine for treatment-resistant unipolar depression: current evidence.

4. Lack of persistent effects of ketamine in rodent models of depression.

5. What is hydroxynorketamine and what can it bring to neurotherapeutics?

6. Daily oral ketamine for the treatment of depression and anxiety in patients receiving hospice care: a 28-day open-label proof-of-concept trial.

7. Effects of striatal ΔFosB overexpression and ketamine on social defeat stress-induced anhedonia in mice.

Review 8. Targeting glutamatergic signaling for the development of novel therapeutics for mood disorders.

9. Effect of Ketamine, Thiopental and Ketamine-Thiopental Combination during Electroconvulsive Therapy for Depression.

Review 10. Ketamine and the next generation of antidepressants with a rapid onset of action.